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ABSTRACT
In total, 269 methicillin-resistant Staphylococcus
aureus (MRSA) and 434 methicillin-susceptible
S. aureus (MSSA) isolates were investigated to
determine their macrolide–lincosamide–strep-
togramin B (MLSB) resistance phenotypes and
genotypes. The constitutive phenotype (61.3% in
MRSA, 1.3% in MSSA) and erm(A) gene predom-
inated among the 261 erythromycin-resistant
MRSA isolates, while the inducible phenotype
(38.7% in MRSA, 94.0% in MSSA) and erm(C)
gene were more prevalent among the 150 eryth-
romycin-resistant MSSA isolates. There was a
higher incidence of the MLSB inducible pheno-
type compared with other countries, perhaps
because MLSB antibiotics are not recommended
as ﬁrst-line agents against S. aureus in Japan.
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Cross-resistance to macrolides, lincosamides and
streptogramin B (MLSB) antibiotics in Staphylococ-
cus aureus is encoded by erythromycin ribosome
methylation (erm) genes. Such resistance can be
either constitutive or inducible. The MLSB indu-
cible phenotype can result in clindamycin resist-
ance in erythromycin-resistant S. aureus, thus
causing clinical failure of clindamycin treatment
[1]. Standard susceptibility tests, in addition to the
double-disk diffusion test (D-test), are needed to
determine the MLSB resistance type [2]. Other
resistance mechanisms, e.g., the msr(A) and
msr(B) macrolide efﬂux pumps and enzymic
modiﬁcation encoded by the ere(A) and ere(B)
genes, have also been described in S. aureus [3,4].
Therefore, identiﬁcation of the gene causing MLSB
resistance is important clinically.
The purpose of the present study was to
determine the mechanism of MLSB resistance,
phenotypically using the D-test and genotypically
using PCR to detect the erm(A), erm(B), erm(C),
msr(A) ⁄ (B), ere(A) and ere(B) genes, among com-
munity-acquired (CA) methicillin-resistant S. au-
reus (MRSA), hospital-acquired (HA) MRSA and
methicillin-susceptible S. aureus (MSSA).
In total, 703 clinical isolates from individual
patients, consisting of 269 MRSA and 434 MSSA
isolates, were collected between 2001 and 2006
from ﬁve general hospitals and two paediatric
clinics in Niigata, Japan. The prevalence of MRSA
in Japan has been reported recently to be 45.9%
[5]. MRSA isolates included 125 Panton–Valentine
leukocidin (PVL)-negative HA-MRSA isolates
from the blood, sputum, pleural effusion, abscess,
skin or urine of adult patients, 117 PVL-negative
HA-MRSA isolates from neonates in the neonatal
intensive care unit, and 27 CA-MRSA isolates
(including two PVL-positive isolates, NN1 and
NN12 [6]) from bullous impetigo or nasal swabs
from children. MSSA isolates were from skin
infections (e.g., bullous impetigo) or nasal
swabs from adults and children. All isolates were
stored at )80C. HA-MRSA and CA-MRSA were
classiﬁed according to deﬁnitions published pre-
viously [7].
For bacterial growth, Luria–Bertani broth (Dif-
co Laboratories, Detroit, MI, USA) and Mueller–
Hinton agar (Becton Dickinson, Sparks, MD,
Corresponding author and reprint requests: T. Yamamoto,
Division of Bacteriology, Department of Infectious Disease
Control and International Medicine, Niigata University Gradu-
ate School of Medical and Dental Sciences, 757 Ichibanchou,
Asahimachidori, Niigata 951-8510, Japan
E-mail: tatsuoy@med.niigata-u.ac.jp
Research Notes 325
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 316–346
USA) were used. For susceptibility testing, the
CLSI disk-diffusion method was used [8], with
disks containing 2 lg of clindamycin, 15 lg of
erythromycin and 15 lg of azithromycin (Nissui
Pharmaceutical Co., Tokyo, Japan). Inducible
resistance to clindamycin was detected by D-test
as described previously [2]. In this study, a double
D-test was performed simultaneously in which
15-lg erythromycin and 15-lg azithromycin
disks were placed 12 mm from a 2-lg clindamy-
cin disk (in the centre) and 26 mm from each
other (edge-to-edge). After incubation for 18 h at
35C, the D-test result was interpreted as either
constitutive, inducible (subdivided into D and D+
phenotypes [9]) or another resistance type (resist-
ance to erythromycin and azithromycin, but no
inducible clindamycin resistance). The MLSB
resistance genes erm(A), erm(B), erm(C),
msr(A) ⁄ (B), ere(A) and ere(B) were detected by
PCR using primers described previously [10,11].
PCR products were visualised following electro-
phoresis in agarose 1.5% w ⁄ v gels. Data analysis
was performed using the chi-square and Fisher
exact tests, with p values <0.05 considered sig-
niﬁcant.
Among the 269 MRSA and 434 MSSA isolates,
261 MRSA (97.0%) and 150 MSSA (34.6%) isolates
were resistant to one ormoreMLSB agents. The two
PVL-positive CA-MRSA isolates were susceptible
to MLSB agents. The clindamycin resistance rate
was 59.5% amongMRSA isolates and 0.5% among
MSSA isolates, while erythromycin and azithro-
mycin resistance was observed among 97.0% of
MRSA isolates and 34.6% of MSSA isolates. A
relationship between use of antibiotics and acqui-
sition of resistance is generally accepted [12], and
the present data suggest that stronger antibiotic
pressure is exerted on MRSA than on MSSA.
The distribution of MLSB resistance phenotypes
and genotypes is summarised in Table 1. None of
the S. aureus isolates in this collection carried the
ere(A) or ere(B) genes. The double D-test results
showed that erythromycin and azithromycin
were similarly effective in inducing clindamycin
resistance (data not shown). Almost all of the
erythromycin-resistant clindamycin-susceptible
isolates (including MRSA and MSSA) that had
the MLSB inducible phenotype were found to
carry an erm gene (97.2%; 242 of 249 isolates),
while the remaining seven (2.8%) isolates har-
boured the msr(A) ⁄ (B) gene. Hence, all erythro-
mycin-resistant, clindamycin-susceptible isolates
should be tested with the D-test, and microbiology
laboratories should warn clinicians concerning
the possibility of MLSB inducible resistance and
the consequent risk of clindamycin use.
Among erythromycin-resistant isolates in this
study, MLSB constitutive resistance (61.3%MRSA
vs. 1.3% MSSA; p <0.05) and the erm(A) gene
(95.0% MRSA vs. 53.3% MSSA; p <0.05) were
predominant among MRSA strains, while MLSB
inducible resistance (38.7% MRSA vs. 94.0%
MSSA; p <0.05) and the erm(C) gene (11.5%
MRSA vs. 42.0% MSSA; p <0.05) were more
prevalent among MSSA strains. These results are
consistent with most previous reports [4,13–17],
except for those concerning Greece, where pre-
dominance of the erm(C) gene among MRSA
isolates has been reported [13]. The present study
also revealed a higher incidence of the MLSB
Table 1. MLSB phenotypes and genotypes among erythromycin-resistant Staphylococcus aureus isolates from Japan
Genotype




n = 160 (61.3%)
MLSB
inducible
n = 101 (38.7%)
Other
type





















n = 2 (1.3%)
MLSB
inducible
n = 141 (94.0%)
Other
type
n = 7 (4.7%)
erm(A) 14 140 3 74 0 0 0 79 0 310
erm(B) 0 0 0 0 0 0 1 0 0 1
erm(C) 0 0 4 9 (D+ 6)c 0 0 1 61 (D+ 59)c 0 75 (D+ 65)c
erm(A), erm(C) 1 4 0 11 0 0 0 1 0 17
erm(A), erm(C), msr(A) ⁄ (B) 0 1 0 0 0 0 0 0 0 1
msr(A) ⁄ (B) 0 0 0 0 0 0 0 0 7d 7
aOf 269 MRSA isolates, 261 (97.0%) were resistant to MLSB agents, and eight (3.0%) were susceptible to MLSB agents.
bOf 434 MSSA isolates, 150 (34.6%) were resistant to MLSB agents, and 284 (65.4%) were susceptible to MLSB agents.
cD+ phenotype; D-shaped zone with small colonies growing up to the clindamycin disk in an otherwise clear zone.
dSeven isolates harbouring msr(A) ⁄ (B) were resistant to erythromycin and azithromycin.
MLSB, macrolides, lincosamides and streptogramin B; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; CA-MRSA, community-acquired MRSA;
HA-MRSA, hospital-acquired MRSA.
326 Clinical Microbiology and Infection, Volume 13 Number 3, March 2007
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 316–346
inducible phenotype in Japan (38.7% MRSA,
94.0% MSSA) than in Europe (7.1% MRSA,
55.9% MSSA) [14], Turkey (8.2% MRSA, 30.8%
MSSA) [15], France (14.6% MRSA, 75.6% MSSA)
[16], Germany (9.0% MRSA, 86.6% MSSA) [4]
and the USA (9.1% and 14.9% in two centres for
MRSA; 86.1% and 54.4% in two centres for
MSSA) [17]. Such differences in the incidence of
MLSB inducible resistance could be caused by
differences in guidelines for drug usage in Japan,
where MLSB antibiotics are not recommended as
ﬁrst-line agents against S. aureus.
CA-MRSA and HA-MRSA showed almost the
same prevalence of the MLSB phenotype (Ta-
ble 1). Thus, 30–40% of MLSB-resistant MRSA
isolates had the potential to express MLSB indu-
cible resistance, regardless of MRSA origin (hos-
pital or community).
To our knowledge, this is the ﬁrst report of
MLSB resistance phenotypes and genotypes in
Japan. The incidence of MLSB phenotypes and
genotypes varies according to country, patterns of
infections and drug use. It is suggested that MLSB
resistance in S. aureus should be under constant
surveillance in every country and region.
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